Detail akcie Recordati online

Business Summary: Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Recordati Industria Chmc Frmctc SpA revenues increased 12% to EUR1.96B. Net income decreased 4% to EUR326.3M. Revenues reflect Rare diseases segment increase of 29% to EUR782.2M, Specialty & Primary care segment increase of 3% to EUR1.03B, United States segment increase of 30% to EUR375.4M, Other international segment increase of 23% to EUR258.9M, Russia segment increase of 17% to EUR126.5M.